Jiangsu Aidea Pharmaceutical News

Eddy Pharmaceuticals 2024 Annual Results Express Announcement

SZSIFeb 27 11:00 ET · Announcements

Jiangsu Aidea Pharmaceutical (688488.SH): Net loss of 0.13 billion yuan for the year 2024.

Gelonghui February 27丨Jiangsu Aidea Pharmaceutical (688488.SH) announced the performance report for 2024. During the reporting period, the company's total operating revenue was 419.265 million yuan, an increase of 1.92% compared to the same period last year; the operating profit was -151.8265 million yuan, which is a decrease of 64.94% compared to the same period last year; the total profit was -153.0564 million yuan, which represents a decrease of 66.21% compared to the same period last year; the net income attributable to the owners of the parent company was -129.9185 million yuan, a decrease of 70.79% compared to the same period last year; the net income attributable to the owners of the parent company after deductions.

Gelonghui FinanceFeb 27 05:21 ET

Eddy Pharmaceuticals 2024 Annual Results Forecast

SZSIJan 17 11:00 ET · Announcements

Jiangsu Aidea Pharmaceutical (688488.SH): Elected Fu Heling as Director.

Gelonghui, January 3rd丨Jiangsu Aidea Pharmaceutical (688488.SH) announced that on January 3, 2025, the company will hold the first meeting of the third Board of Directors, where all directors unanimously agreed to elect Mr. Fu Helian as the chairman of the third Board of Directors.

Gelonghui FinanceJan 3 06:41 ET

Jiangsu Aidea Pharmaceutical (688488.SH): New core technical personnel identified as Qin Hong, Li Qide, and Sun Tie.

Jiangsu Aidea Pharmaceutical (688488.SH) issued a notice that the company's senior management and core technical personnel Hong ...

Zhitong FinanceDec 18, 2024 06:19 ET

Insiders With Their Considerable Ownership Were the Key Benefactors as Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Touches CN¥4.1b Market Cap

Simply Wall StNov 10, 2024 23:07 ET

Eddy Pharmaceuticals: Eddy Pharmaceuticals Third Quarter 2024 Report

SZSIOct 30, 2024 12:00 ET · Announcements

Eddy Pharmaceuticals 2024 Third Quarter Report

SZSIOct 30, 2024 12:00 ET · Announcements

Director and Vice President Wang Jun of Jiangsu Aidea Pharmaceutical (688488.SH) completed the shareholding of 0.6921 million shares.

Jiangsu Aidea Pharmaceutical (688488.SH) announced that the director and vice president Wang Jun has cumulatively reduced his shareholding through centralized bidding...

Zhitong FinanceOct 22, 2024 07:28 ET

China Accepts Jiangsu Aidea Pharma's New Indication for HIV Medication

MT NewswiresOct 9, 2024 05:07 ET

Investor Optimism Abounds Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) But Growth Is Lacking

Simply Wall StOct 6, 2024 22:35 ET

Jiangsu Aidea Pharmaceutical Withdraws Marketing Authorization Application for HIV Tablets

MT NewswiresSep 27, 2024 05:55 ET

Jiangsu Aidea Pharmaceutical (688488.SH): Withdrawal of the new indication application for Aino Weilin tablets.

Gelonghui September 26th | jiangsu aidea pharmaceutical (688488.SH) announced that the company has scientifically formulated differentiated market strategy based on evidence-based medicine data, product characteristics, patent duration, etc. for antiretroviral drugs. According to the company's market strategy, the company has proactively applied to withdraw the marketing authorization application for the new indication of enofovir tablets, and has recently obtained approval from the National Medical Products Administration. As of the date of this announcement, the single-compound formulation of enofoside tablets containing enofoside as an ingredient has made smooth progress in the application for new indications, and its marketing authorization application has completed the technical review work, and is currently in the process of document preparation and review and approval. The company will continue

Gelonghui FinanceSep 26, 2024 07:13 ET

Star Evening News | Xi'an Bright Laser Technologies plans to invest 1 billion yuan to build a material production line. Jiangsu Aidea Pharmaceutical has completed the acquisition of 31.161% equity of Nanda Pharmaceuticals.

1. Guangdong Jiayuan Technology signed the "Investment Intention Termination Agreement" with the Meixian District People's Government of Meizhou City; 2. Xi'an Bright Laser Technologies, opt machine vision tech co., ltd., NAIKE Equipment disclosed the repurchase plan; 3. Shanghai Allist Pharmaceuticals Co., Ltd.: AST2303 slice obtained the drug clinical trial approval notice.

cls.cnSep 23, 2024 09:04 ET

Aidea Pharma Pledges Subsidiary's 51% Stake for 90 Million Yuan Loan; Shares Drop 5%

MT NewswiresSep 18, 2024 01:14 ET

Jiangsu Aidea Pharmaceutical 2024 Half-Year Report

SZSIAug 22, 2024 12:00 ET · Announcements

Summary of jiangsu aidea pharmaceutical's 2024 Interim Report

SZSIAug 22, 2024 12:00 ET · Announcements

Gelonghui announcement selection | Hubei Heyuan Gas Co., Ltd.: plans to invest 2.2 billion yuan in the construction of electronic gas center and global headquarters in Donghu Comprehensive Bonded Zone; Sailun Group: net income in the first half of the yea

Signing Project: Harbin Pharmaceutical Group (600664.SH): plans to invest 9.162 million yuan in the renovation project of Harbin Pharmaceutical Institute of Traditional Chinese Medicine; plans to invest 10.06 million yuan in the heating network project in the Nanzhiliu Factory of Harbin Pharmaceutical Co., Ltd. Chongqing Taiji Industry (600129.SH): Subsidiary Tongjunge Pharmaceutical Factory plans to build Phase I of the new plant area; Hubei Heyuan Gas Co., Ltd. (002971.SZ): plans to invest 2.2 billion yuan in the construction of the electronic gas center and global headquarters in Donghu Comprehensive Bonded Zone; Hunan Boyun New Materials (002297.SZ): plans to invest 60.006 million yuan in the renovation of Boyun New Materials Innovation Industrial Park.

Gelonghui FinanceAug 22, 2024 10:48 ET

Jiangsu Aidea Pharmaceutical (688488.SH): plans to privately place shares to the controlling shareholder to raise no more than 0.1 billion yuan.

On August 22nd, Aidea Pharmaceuticals (688488.SH) announced the plan to issue A-shares to specific individuals in 2024. The recipient of this issuance is Mr. Fu Heliang, who is one of the company's actual controllers. Mr. Fu intends to subscribe to all stocks issued in this offering using cash. As Mr. Fu Heliang is a related party of the company, this issuance of stocks to specific individuals constitutes a related transaction. The total amount of funds raised through this issuance to specific individuals does not exceed 0.1 billion yuan (including this amount), and the net amount of funds raised after deducting the relevant issuance expenses is intended to be used entirely for supplementary working capital.

Gelonghui FinanceAug 22, 2024 09:24 ET

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Insiders, Who Hold 28% of the Firm Would Be Disappointed by the Recent Pullback

Simply Wall StJul 30, 2024 20:34 ET